查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1584716

原料藥藥 CDMO 市場：依藥物、產品、合成、工作流程、應用分類 - 2025-2030 年全球預測

Active Pharmaceutical Ingredients CDMO Market by Drug, Product, Synthesis, Workflow, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年原料原料藥CDMO市場規模為1,148.5億美元，預計2024年將達到1,264.2億美元，複合年成長率為10.38%，預計2030年將達2,293.9億美元。

活性藥物原料藥（API）CDMO（受託製造廠商）市場專注於藥物開發和製造流程的外包，這對製藥公司至關重要。由於 API 是藥品的生物活性成分，因此 CDMO 市場由這些物質的合成、製程開發和大規模生產來定義。對 CDMO 的需求源自於製藥公司簡化業務、降低成本並專注於核心研發活動的需求。 原料藥應用涵蓋循環系統、腫瘤學和神經學等多種治療領域，最終用途市場包括製藥公司、生技公司和學名藥製造商。目前，關鍵的成長要素包括生技藥品和生物相似藥的進步、慢性病的增加以及對個人化醫療的需求不斷成長。新的商機在於轉向更綠色的製造流程以及整合人工智慧以實現流程最佳化。然而，嚴格的監管要求、供應鏈中斷和競爭加劇等挑戰可能會抑制市場成長。與外包相關的品質問題和潛在的智慧財產權風險也是阻礙因素。為了應對這些挑戰並利用機遇，連續製造製程和奈米技術應用的創新可以提供重要的成長途徑。此外，利用巨量資料分析和機器學習的數位轉型提高流程效率也將開拓新的研發和業務發展領域。 API CDMO 市場呈現動態特徵，研究合作和策略聯盟成為獲得市場佔有率的關鍵策略。對研發和技術適應的持續投資可以幫助企業在不斷變化的市場環境中提高競爭力。

主要市場統計
基準年[2023] 1148.5億美元
預測年份 [2024] 1264.2億美元
預測年份 [2030] 2293.9億美元
複合年成長率（%） 10.38%

市場動態：快速發展的原料藥藥 CDMO 市場的關鍵市場洞察

原料原料藥CDMO 市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 學名藥需求增加，生物製藥消費增加
    • 小分子的成長，原料藥(API) 的複雜性增加
    • 對標靶癌症治療和其他治療的需求不斷成長
  • 市場限制因素
    • 外包時的合規問題
  • 市場機會
    • 增加原料原料藥CDMO 的研發投入
    • 抗癌藥物研究進展
  • 市場挑戰
    • 原料藥CDMO 的嚴格監管合規要求

波特五力：駕馭原料藥藥 CDMO 市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解原料原料藥CDMO 市場的外部影響

外部宏觀環境因素在塑造原料原料藥CDMO 市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解原料藥藥 CDMO 市場的競爭狀況

藥物原料藥CDMO 市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣原料藥藥 CDMO 市場供應商的績效評估

FPNV定位矩陣是評估原料原料藥CDMO市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議 規劃原料原料藥CDMO 市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，原料藥藥 CDMO 市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 學名藥需求增加，生物製藥消費增加
      • 小分子的成長，活性藥物成分 (API) 的複雜性增加
      • 對標靶癌症和其他醫療治療的需求不斷成長
    • 抑制因素
      • 外包時的合規問題
    • 機會
      • 增加原料藥CDMO研發投入
      • 腫瘤藥物研究持續變得更加複雜
    • 任務
      • API CDMO 的嚴格監管合規要求
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 依藥物分類的原料藥藥 CDMO 市場

  • 非專利的
  • 創新的

第7章 藥物原料藥CDMO 市場：依產品

  • 抗體藥物複合體
  • 非常強大的活性藥物成分
  • 傳統藥物活性成分

第8章 合成原料藥藥 CDMO 市場

  • 生物技術
  • 合成

第 9 章原料藥藥 CDMO 市場：依工作流程

  • 臨床
  • 商業的

第10章醫藥原料藥CDMO市場：依應用分類

  • 心血管
  • 糖尿病
  • 青光眼
  • 荷爾蒙
  • 腫瘤學

第11章：北美和南美藥物原料藥CDMO市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太原料藥藥CDMO市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲/中東/非洲原料原料藥CDMO市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • 5N Plus
  • AR Life Sciences Pvt. Ltd.
  • AbbVie Inc.
  • abcr GmbH
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Corden Pharma International GmbH
  • Curia Global, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Evonik Industries AG
  • IOL Chemicals and Pharmaceuticals Limited
  • Jungbunzlauer Suisse AG
  • Lonza Group Ltd.
  • Lupin Limited
  • Minafin Group
  • Mylan Inc.
  • Olon SpA
  • Piramal Group
  • PMC Group, Inc.
  • Polpharma SA
  • Recipharm AB
  • Samsung Biologics
  • SEQENS
  • Siegfried AG
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Tiefenbacher API+Ingredients GmbH & Co. KG
  • Xellia Pharmaceuticals ApS by Novo Holdings A/S
Product Code: MRR-575EAC9DD1AE

The Active Pharmaceutical Ingredients CDMO Market was valued at USD 114.85 billion in 2023, expected to reach USD 126.42 billion in 2024, and is projected to grow at a CAGR of 10.38%, to USD 229.39 billion by 2030.

The active pharmaceutical ingredients (API) CDMO (Contract Development and Manufacturing Organization) market focuses on the outsourcing of drug development and manufacturing processes which are crucial for pharmaceutical companies. APIs are the biologically active components in drugs; thus, the CDMO market is defined by the synthesis, process development, and large-scale production of these substances. The necessity for CDMOs arises from the need for pharmaceutical companies to streamline operations, reduce costs, and focus on core R&D activities. Applications of APIs span across various therapeutic areas such as cardiovascular, oncology, and neurology, with end-use markets including pharmaceutical companies, biotechnology firms, and generic drug manufacturers. Currently, key growth factors include advancements in biologics and biosimilars, increasing prevalence of chronic diseases, and the rising demand for personalized medicine. Emerging opportunities are grounded in the shifts towards greener manufacturing processes and artificial intelligence integration for process optimization. However, challenges such as stringent regulatory requirements, supply chain disruptions, and high competition may restrain market growth. Limitations also include the potential for quality concerns and IP risks associated with outsourcing. To address these challenges and leverage opportunities, innovations in continuous manufacturing processes and nanotechnology applications could present significant growth avenues. The digital transformation with the use of big data analytics and machine learning for enhanced process efficiencies also opens up new research and business development fields. The API CDMO market showcases a dynamic nature with collaborations and strategic partnerships emerging as key strategies to capture market share. With sustained investment in R&D and technology adaptation, companies can enhance their competitive edge in this evolving market landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 114.85 billion
Estimated Year [2024] USD 126.42 billion
Forecast Year [2030] USD 229.39 billion
CAGR (%) 10.38%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Active Pharmaceutical Ingredients CDMO Market

The Active Pharmaceutical Ingredients CDMO Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising demand for generic drugs and increasing consumption of biopharmaceuticals
    • Growth of small molecules, rising active pharmaceutical ingredient (API) complexity
    • Growing demand for targeted cancer and other medical treatments
  • Market Restraints
    • Issues associated with compliances while outsourcing
  • Market Opportunities
    • Increasing R&D investment for active pharmaceutical ingredients CDMO
    • Proliferating sophistication in oncology drug research
  • Market Challenges
    • Stringent regulatory compliance requirements for API CDMO

Porter's Five Forces: A Strategic Tool for Navigating the Active Pharmaceutical Ingredients CDMO Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Active Pharmaceutical Ingredients CDMO Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Active Pharmaceutical Ingredients CDMO Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Active Pharmaceutical Ingredients CDMO Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Active Pharmaceutical Ingredients CDMO Market

A detailed market share analysis in the Active Pharmaceutical Ingredients CDMO Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Active Pharmaceutical Ingredients CDMO Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Active Pharmaceutical Ingredients CDMO Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Active Pharmaceutical Ingredients CDMO Market

A strategic analysis of the Active Pharmaceutical Ingredients CDMO Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Active Pharmaceutical Ingredients CDMO Market, highlighting leading vendors and their innovative profiles. These include 5N Plus, A. R. Life Sciences Pvt. Ltd., AbbVie Inc., abcr GmbH, Biocon Limited, Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Corden Pharma International GmbH, Curia Global, Inc., Dr. Reddy's Laboratories Ltd., Evonik Industries AG, IOL Chemicals and Pharmaceuticals Limited, Jungbunzlauer Suisse AG, Lonza Group Ltd., Lupin Limited, Minafin Group, Mylan Inc., Olon S.p.A., Piramal Group, PMC Group, Inc., Polpharma SA, Recipharm AB, Samsung Biologics, SEQENS, Siegfried AG, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Tiefenbacher API + Ingredients GmbH & Co. KG, and Xellia Pharmaceuticals ApS by Novo Holdings A/S.

Market Segmentation & Coverage

This research report categorizes the Active Pharmaceutical Ingredients CDMO Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug, market is studied across Generics and Innovative.
  • Based on Product, market is studied across Antibody Drug Conjugate, Highly Potent Active Pharmaceutical Ingredient, and Traditional Active Pharmaceutical Ingredient.
  • Based on Synthesis, market is studied across Biotech and Synthetic.
  • Based on Workflow, market is studied across Clinical and Commercial.
  • Based on Application, market is studied across Cardiovascular, Diabetes, Glaucoma, Hormonal, and Oncology.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising demand for generic drugs and increasing consumption of biopharmaceuticals
      • 5.1.1.2. Growth of small molecules, rising active pharmaceutical ingredient (API) complexity
      • 5.1.1.3. Growing demand for targeted cancer and other medical treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Issues associated with compliances while outsourcing
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing R&D investment for active pharmaceutical ingredients CDMO
      • 5.1.3.2. Proliferating sophistication in oncology drug research
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory compliance requirements for API CDMO
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Active Pharmaceutical Ingredients CDMO Market, by Drug

  • 6.1. Introduction
  • 6.2. Generics
  • 6.3. Innovative

7. Active Pharmaceutical Ingredients CDMO Market, by Product

  • 7.1. Introduction
  • 7.2. Antibody Drug Conjugate
  • 7.3. Highly Potent Active Pharmaceutical Ingredient
  • 7.4. Traditional Active Pharmaceutical Ingredient

8. Active Pharmaceutical Ingredients CDMO Market, by Synthesis

  • 8.1. Introduction
  • 8.2. Biotech
  • 8.3. Synthetic

9. Active Pharmaceutical Ingredients CDMO Market, by Workflow

  • 9.1. Introduction
  • 9.2. Clinical
  • 9.3. Commercial

10. Active Pharmaceutical Ingredients CDMO Market, by Application

  • 10.1. Introduction
  • 10.2. Cardiovascular
  • 10.3. Diabetes
  • 10.4. Glaucoma
  • 10.5. Hormonal
  • 10.6. Oncology

11. Americas Active Pharmaceutical Ingredients CDMO Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Active Pharmaceutical Ingredients CDMO Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Active Pharmaceutical Ingredients CDMO Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 5N Plus
  • 2. A. R. Life Sciences Pvt. Ltd.
  • 3. AbbVie Inc.
  • 4. abcr GmbH
  • 5. Biocon Limited
  • 6. Boehringer Ingelheim International GmbH
  • 7. Cambrex Corporation
  • 8. Catalent, Inc.
  • 9. Corden Pharma International GmbH
  • 10. Curia Global, Inc.
  • 11. Dr. Reddy's Laboratories Ltd.
  • 12. Evonik Industries AG
  • 13. IOL Chemicals and Pharmaceuticals Limited
  • 14. Jungbunzlauer Suisse AG
  • 15. Lonza Group Ltd.
  • 16. Lupin Limited
  • 17. Minafin Group
  • 18. Mylan Inc.
  • 19. Olon S.p.A.
  • 20. Piramal Group
  • 21. PMC Group, Inc.
  • 22. Polpharma SA
  • 23. Recipharm AB
  • 24. Samsung Biologics
  • 25. SEQENS
  • 26. Siegfried AG
  • 27. Sun Pharmaceutical Industries Limited
  • 28. Teva Pharmaceutical Industries Ltd.
  • 29. Tiefenbacher API + Ingredients GmbH & Co. KG
  • 30. Xellia Pharmaceuticals ApS by Novo Holdings A/S

LIST OF FIGURES

  • FIGURE 1. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET RESEARCH PROCESS
  • FIGURE 2. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET DYNAMICS
  • TABLE 7. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GENERICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY INNOVATIVE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ANTIBODY DRUG CONJUGATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY BIOTECH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY HORMONAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 236. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET, FPNV POSITIONING MATRIX, 2023